KOSDAQBiotech & Pharma314140

RPbio

₩5,110▲ 2.40%2026-11-18 close
Market Cap
₩44.3B
Turnover
₩41,771,350
Volume
8.2K
Shares out.
8.7M
PER
4.9×
PBR
0.4×
EPS
₩1,023
Dividend Yield
1.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩50 per share · Prices as of the 2026-11-18 close

01

Report overview

RPbio: Soft-Capsule CDMO, Profit Structure Still Under Review

RPbio returned to annual operating profit in 2025 and grew quarterly sales and operating profit through the third quarter of 2026, but whether those earnings can hold is a question for the next annual report.

  1. 1

    Operating profit was KRW 5.09 billion in 2025, reversing the 2024 operating loss, and net income attributable to controlling shareholders was KRW 4.68 billion.

  2. 2

    Press reports say the cost of sales ratio fell from 94.2% in 2024 to 87.5% in the first quarter of 2026, and cost improvement is cited as the core of the earnings recovery.

  3. 3

    Net income attributable to controlling shareholders over the last four quarters totaled KRW 8.86 billion, while third-quarter 2026 operating profit of KRW 2.3 billion fell 43.8% from the prior quarter.

  4. 4

    Utilization at the health-food plant rose to 93% in the second quarter of 2026, narrowing spare capacity, and expansion or added lines are being discussed.

  5. 5

    The next checkpoints are the launch of the first domestic medicinal jelly product and the full-year 2026 operating profit in the annual report, compared with the company's KRW 12 billion target.

02

Business structure

RPbio makes soft capsules and supplies drugs and health functional foods through OEM and ODM contract manufacturing. According to a Korea IR Consortium analysis, the 2024 sales mix was 58.0% health functional foods, 41.5% drugs and 0.5% other items.

The Hwaseong Hyangnam and Mado plants together are described as having a production capacity of KRW 280 billion. Reports say the Mado health-food plant can produce up to 1.08 billion capsules a year. Its clients are mainly large domestic drugmakers whose flagship products it manufactures under contract.

Its proprietary technologies, New Neosol for drug release and New Neogel for capsule film stability, are applied across many products and are cited as differentiators. Press reports say it holds a majority share of the domestic OTC soft-capsule market.

Its formats have widened to blister jellies (omega-3, lutein, multivitamins) and a red ginseng blister jelly. The company says it has secured four individually recognized functional ingredients for health foods.

Based on filing-based figures for the first quarter of 2026, health functional foods accounted for KRW 18.5 billion and OTC drugs for KRW 16.6 billion. Compared with large listed biologics CDMO companies such as Samsung Biologics and Celltrion, RPbio focuses on a narrower area centered on soft-capsule formats.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩33.2B₩300M0.8%
2025Q4₩33.3B₩700M2.1%
2026Q1₩35.1B₩2.4B6.9%
2026Q2₩39.8B₩4.1B10.3%
2026Q3₩41.1B₩2.3B5.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩138.1B₩9.6B₩4.3B7.0%4.7%90.0%
2023₩151B₩6.6B₩5.4B4.4%5.3%61.8%
2024₩124B-₩700M-₩900M−0.6%−0.9%55.9%
2025₩136.2B₩5.1B₩4.7B3.7%4.4%45.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

On a filed annual basis, revenue was KRW 138.1 billion in 2022, rose to KRW 151 billion in 2023 (up 9.4% year on year), fell to KRW 124 billion in 2024 (down 17.9%), and recovered to KRW 136.2 billion in 2025 (up 9.9%). Among 2022 to 2025, 2023 was the largest year and 2024 the smallest.

Operating profit fell from KRW 9.65 billion in 2022 to KRW 6.62 billion in 2023 (down 31.3%), turned into an operating loss of KRW 694 million in 2024, and returned to operating profit of KRW 5.09 billion in 2025. Operating margins were 7.0% in 2022, 4.4% in 2023, -0.6% in 2024 and 3.7% in 2025.

Net income attributable to controlling shareholders was KRW 5.44 billion in 2023 (up 26.0%), then a loss of KRW 907 million in 2024, and returned to profit of KRW 4.68 billion in 2025. Net income including non-controlling interests also turned positive in 2025, at KRW 4.68 billion.

The company attributed the 2025 turnaround to higher sales from expanded orders for its main products and new customers, higher plant utilization and an improved cost structure. Press reports put the cost of sales ratio at 94.2% in 2024, 89.8% in 2025 and 87.5% in the first quarter of 2026.

Quarterly revenue went from KRW 33.2 billion in the third quarter of 2025 to KRW 33.3 billion, KRW 35.1 billion, KRW 39.8 billion and KRW 41.1 billion in the third quarter of 2026, a run of four consecutive quarterly increases from the fourth quarter of 2025 through the third quarter of 2026.

Quarterly operating profit was KRW 273 million in the third quarter of 2025, KRW 684 million, KRW 2.42 billion, KRW 4.09 billion and KRW 2.3 billion in the third quarter of 2026, which was down 43.8% from the prior quarter.

The drivers of that quarterly swing should be traced through the cost of sales and selling and administrative expense detail in the annual report. Net income attributable to controlling shareholders over the last four quarters totaled KRW 8.86 billion.

The debt-to-equity ratio fell from 90.0% in 2022 to 45.8% in 2025, and operating cash flow was KRW 12.5 billion in 2025.

05

Industry analysis

RPbio's demand is recovering on the health-food side. Reports based on its semi-annual filing put utilization at its health-food plant at 86% in 2024, 90% at the end of 2025 and 93% in the second quarter of 2026. Industry sources say OEM and ODM orders for health foods have risen sharply.

Some observers say utilization is close to its practical limit. An August 2026 report linked order growth to a drug pricing reform that has pushed traditional drugmakers to expand into health foods.

In the same report, another industry source said health-food businesses do not all carry high margins and are often pursued for revenue diversification.

In cycle terms, the soft-capsule drug business is a mature, established demand base, and the company is trying to lift profitability by raising the share of higher-value formats such as blister jellies.

The Korea IR Consortium said the commercialization of new formats is raising the share of higher-value products and increasing customer orders.

On regulation, the government's review of safety-essential medicines has accelerated, and RPbio validated a 1 mm foreign-matter inspection system, so tougher quality standards may act as a barrier to entry.

Overseas, the company said in June 2026 that the Mado health-food plant passed a US FDA production site inspection with a voluntary action indicated classification.

Against peers, it is a leading contract manufacturer specialized in soft-capsule formats in Korea, and its business structure differs from listed biologics CDMO companies.

06

Outlook

The company set a 2026 operating profit target of KRW 12 billion in January 2026. Alongside that target, it said it would streamline production processes, improve margins and grow new formats such as medicinal jelly, gelatin formulations and blister jellies.

Reports say a high-content vitamin medicinal jelly that has received marketing approval is slated for full launch in the second half of 2026. Other reports say the first domestic medicinal jelly could launch within 2026.

A red ginseng functional blister jelly was announced for commercialization on February 27, 2026, after a Ministry of Food and Drug Safety safety review. The company also obtained a new-formulation approval from the ministry for its Neochu product.

In October 2026, completion of a 24-month long-term storage test for a bulk bottle pack of pexofenadine was reported. An industry source said the company is considering expanding capacity at the health-food plant or improving efficiency over the long term.

The scale and timing of any expansion will be clearer when the company discloses it. Overseas, the company plans to expand ODM exports through a global network centered on the United States and Asia.

Quarterly operating profit was KRW 2.42 billion in the first quarter of 2026, KRW 4.09 billion in the second and KRW 2.3 billion in the third, so the gap to the KRW 12 billion annual target will be measured in the full-year 2026 annual report. Whether new formats grow as a share of total sales is another point to check in the next periodic report.

07

Valuation

PER
4.9×
PBR
0.4×
ROE
8.1%
EPS
₩1,023
BPS
₩13,137
Dividend per share
₩50

The starting point for valuation is how fast earnings are recovering and how large net assets are. The move from a loss in 2024 to a profit in 2025 makes earnings-based multiples hard to compare directly with the loss period.

Measured against net income attributable to controlling shareholders over the last four quarters, KRW 8.86 billion, quarterly swings make multiples volatile. Controlling-shareholder equity at the end of 2025 was KRW 107.2 billion, and market capitalization sits below that net asset level.

The debt-to-equity ratio fell from 90.0% in 2022 to 45.8% in 2025, so financial burden has declined. Operating cash flow of KRW 12.5 billion in 2025 exceeded net income attributable to controlling shareholders of KRW 4.68 billion.

Comparisons with listed peers are difficult because soft-capsule contract manufacturing and biologics CDMO have different business structures.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Earnings recovery

RPbio moved from an operating loss in 2024 to operating profit of KRW 5.09 billion in 2025, and net income attributable to controlling shareholders over the last four quarters totaled KRW 8.86 billion. Press reports put the cost of sales ratio at 87.5% in the first quarter of 2026, down from 94.2% in 2024.

Quarterly revenue has risen for four consecutive quarters from the fourth quarter of 2025 through the third quarter of 2026.

Expansion of higher-value formats

Commercialization of blister jellies and a red ginseng blister jelly is broadening the product range. The first domestic medicinal jelly is slated for launch in the second half of 2026. The Korea IR Consortium said new-format launches are raising the share of higher-value products.

Health-food demand and plant utilization

Utilization at the health-food plant rose from 86% in 2024 to 93% in the second quarter of 2026. Industry sources say rising OEM and ODM orders have pushed existing capacity close to its limit. An August 2026 report linked order growth to traditional drugmakers expanding into health foods after a drug pricing reform.

09

Bear factors

Quarterly earnings volatility

Third-quarter 2026 operating profit of KRW 2.3 billion fell 43.8% from the prior quarter. Compared with KRW 2.42 billion in the first quarter and KRW 4.09 billion in the second quarter of 2026, quarterly swings are large.

The company posted an operating loss as recently as 2024, so the duration of the profit run is still a short data series.

Margin limits in health foods

An industry source has noted that health-food businesses do not all carry high margins. The cost of sales ratio was still 87.5% in the first quarter of 2026. The operating margin was 3.7% in 2025, low single digits.

Client concentration and management changes

Revenue depends on contract volumes from large domestic drugmakers. Kim Hyun-sun joined as chief executive officer in January 2026, became a co-CEO in March 2026, and resigned in June 2026, leaving Yoon Jae-hoon as sole CEO. How the leadership change affects pursuit of the KRW 12 billion operating profit target needs to be checked.

10

Risk factors

Regulation and policy

Drug price cuts and reviews of the safety-essential medicines system are reshaping the operating environment. Such changes could lift health-food orders as traditional drugmakers expand, but drug price adjustments could also affect demand for client products. Tougher quality standards also bring equipment investment needs.

Management and governance

A co-CEO structure of Yoon Jae-hoon and Kim Hyun-sun took effect on March 31, 2026, and after Kim resigned on June 30, 2026, Yoon became sole CEO. Leadership changes can affect the continuity of medium-term strategy. Who executes the operating profit target and overseas expansion plan needs to be confirmed.

Utilization and investment burden

Utilization at the health-food plant is 93%, leaving little spare capacity. Expansion or added lines would require equipment investment, and the scale and timing will be set by company announcements.

Short-term borrowings fell from KRW 25 billion to KRW 16 billion, but how expansion is financed could affect the balance sheet.

11

What to watch next

  1. By end-December 2026

    Whether the first domestic medicinal jelly product launches as planned in the second half of 2026. A launch would be an early sign of higher-value format sales growing.

  2. Late March 2027

    The 2026 annual report. It will show full-year revenue and operating profit against the KRW 12 billion target, fourth-quarter results and the drivers behind the third-quarter operating profit decline.

  3. Mid-May 2027

    The first-quarter 2027 quarterly report. It will show whether the cost of sales ratio holds near 87.5% and how plant utilization changes.

  4. Mid-August 2027

    The 2027 semi-annual report. It will show whether expansion or added lines are disclosed and how overseas ODM orders develop.

12

Overall view

RPbio moved from an operating loss in 2024 to operating profit in 2025, and quarterly profit in the first three quarters of 2026 was well above the third quarter of 2025.

However, third-quarter 2026 operating profit fell from the prior quarter, so the durability of quarterly profit should be judged on a still-short run of data. The main drivers of improvement are a lower cost of sales ratio and higher health-food plant utilization.

Whether new formats grow as a share of higher-value sales is the next point to check. On the balance sheet, the debt-to-equity ratio fell to 45.8% at the end of 2025, while some industry sources note that health-food businesses do not all carry high margins.

Leadership changed during the first half of 2026, and the company has set a 2026 operating profit target of KRW 12 billion. Weak points include dependence on large drugmakers, regulatory changes such as drug price cuts and the safety-essential medicines system, and investment needs if capacity is added.

Strong points include the earnings recovery, the expansion of new formats and the passing of the US FDA inspection.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. file.alphasquare.co.kr
  2. dailypharm.com
  3. saramin.co.kr
  4. m.news.nate.com
  5. comp.fnguide.com
  6. hkn24.com
  7. goinsider.kr
  8. newsis.com
  9. pharm.edaily.co.kr
  10. biotimes.co.kr
  11. wowtv.co.kr
  12. m.news.nate.com
  13. wowtv.co.kr
  14. seoulexchange.kr
  15. alphasquare.co.kr
  16. seoul.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis